Zia Yasaman, Wiener Jeffrey, Snead Margaret Christine, Papp John, Phillips Christi, Flowers Lisa, Medley-Singh Natalie, Costenbader Elizabeth C, Hylton-Kong Tina, Kourtis Athena P
Division of Reproductive Health, U.S. Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
Association of Schools and Programs of Public Health (ASPPH), Washington, District of Columbia, USA.
BMJ Open. 2018 Apr 13;8(4):e019913. doi: 10.1136/bmjopen-2017-019913.
To assess potentially missed sexually transmitted infections (STIs), we compared clinically diagnosed STIs to laboratory-confirmed diagnoses of gonorrhoea (GC), chlamydia (CT) and trichomonas (Tvag).
Secondary analysis of a randomised controlled trial.
We used data and specimens previously collected for the Sino-Implant Study in Kingston, Jamaica.
The Sino-Implant Study randomised 414 women to receive a levonorgestrel implant at either baseline or 3 months post-enrolment to evaluate unprotected sex after implant initiation. This analysis used 254 available vaginal swab samples.
Clinically diagnosed STIs were determined from medical records by assessing clinical impressions and prescriptions. Laboratory-confirmed STIs included GC, CT and Tvag tested by Aptima Combo 2 for CT/GC and Aptima Tvag assays (Hologic, San Diego, California, USA). Log-binomial regression models fit with generalised estimating equations were used to estimate associations of clinically diagnosed STIs with laboratory-confirmed diagnoses and demographic and behavioural characteristics.
Overall, 195 (76.8%) women had laboratory-confirmed STI (CT, GC or Tvag) while only 65 (25.6%) women had clinically diagnosed cervicitis and/or vaginitis during the study period. Clinical diagnosis missed 79.7% of laboratory-confirmed STIs: 85% of GC (n=17/20), 78.8% of CT (n=141/179) and 80.0% of Tvag (n=180/225). Hormonal contraceptive use in the month prior to the study visit was significantly associated with clinical diagnosis at any time point (prevalence ratio (PR): 1.65, 95% CI 1.07 to 2.54). As age increased, clinically missed infections significantly decreased (PR: 0.98 per year increase, 95% CI 0.97 to 1.00).
The prevalence of laboratory-confirmed STIs was much higher than what was captured by clinical diagnosis. GC, CT and Tvag were not accurately detected without lab confirmation. Missed diagnoses decreased with older age. Increased laboratory capacity and refinement of the syndromic approach are needed to protect the health of sexually active Jamaican women.
NCT01684358.
为评估可能漏诊的性传播感染(STIs),我们将临床诊断的性传播感染与淋病(GC)、衣原体(CT)和滴虫(Tvag)的实验室确诊诊断进行了比较。
一项随机对照试验的二次分析。
我们使用了先前在牙买加金斯敦进行的中研植入物研究收集的数据和标本。
中研植入物研究将414名女性随机分为在基线期或入组后3个月接受左炔诺孕酮植入物,以评估植入物启动后的无保护性行为。本分析使用了254份可用的阴道拭子样本。
通过评估临床印象和处方从病历中确定临床诊断的性传播感染。实验室确诊的性传播感染包括通过Aptima Combo 2检测CT/GC以及Aptima Tvag检测法(美国加利福尼亚州圣地亚哥的Hologic公司)检测的GC、CT和Tvag。使用拟合广义估计方程的对数二项回归模型来估计临床诊断的性传播感染与实验室确诊诊断以及人口统计学和行为特征之间的关联。
总体而言,195名(76.8%)女性有实验室确诊的性传播感染(CT、GC或Tvag),而在研究期间只有65名(25.6%)女性有临床诊断的宫颈炎和/或阴道炎。临床诊断漏诊了79.7%的实验室确诊性传播感染:85%的GC(n = 17/20)、78.8%的CT(n = 141/179)和80.0%的Tvag(n = 180/225)。研究访视前一个月使用激素避孕药与任何时间点的临床诊断显著相关(患病率比(PR):1.65,95%置信区间1.07至2.54)。随着年龄增加,临床漏诊感染显著减少(PR:每年增加0.98,95%置信区间0.97至1.00)。
实验室确诊的性传播感染患病率远高于临床诊断所发现的患病率。未经实验室确认无法准确检测出GC、CT和Tvag。漏诊诊断随着年龄增长而减少。需要提高实验室检测能力并完善综合征方法以保护有性行为的牙买加女性的健康。
NCT01684358。